Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations

BRAF(V600E) melanoma patients, despite initially responding to the clinically prescribed anti-BRAF(V600E) therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAF(V600E) mutation, they often eventually diverge a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudevan, S., Flashner-Abramson, E., Alkhatib, Heba, Roy Chowdhury, Sangita, Adejumobi, I. A., Vilenski, D., Stefansky, S., Rubinstein, A. M., Kravchenko-Balasha, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192524/
https://www.ncbi.nlm.nih.gov/pubmed/34112933
http://dx.doi.org/10.1038/s41698-021-00190-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192524/
https://www.ncbi.nlm.nih.gov/pubmed/34112933
http://dx.doi.org/10.1038/s41698-021-00190-3

Ejemplares similares